Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024

Rhea-AI Summary

Supernus Pharmaceuticals, Inc. (SUPN) will report financial and business results for Q4 and full year 2023 on February 27, 2024. The conference call hosted by the President and CEO, Jack Khattar, and CFO, Tim Dec, will provide insights into the company's performance.

ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2023 on Tuesday, February 27, 2024.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2023 financial and business results on Tuesday, February 27, 2024, at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visit www.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Email: peter.vozzo@westwicke.com 

When will Supernus Pharmaceuticals, Inc. report financial and business results for Q4 and full year 2023?

Supernus Pharmaceuticals, Inc. (SUPN) will report financial and business results for the fourth quarter and full year of 2023 on Tuesday, February 27, 2024.

Who will host the conference call to present the financial and business results?

The conference call to present the fourth quarter and full year 2023 financial and business results will be hosted by Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO.

Where can participants access the live webcast of the conference call?

Participants can access the live webcast in the Events & Presentations section of Supernus Pharmaceuticals, Inc.'s Investor Relations website at www.supernus.com/investors.

How long will the webcast be available on the company's website?

The webcast will be available on Supernus Pharmaceuticals, Inc.'s website for 60 days following the live call.